The data on the role of irradiation for DLBCL in the rituximab era are still immature, but in light of results of the clinical trials and observations on PBL, we feel it should still be recommended as an adjuvant to systemic
immunochemotherapy for localised disease.
CD40 is a potential mareer of favorable prognosis in patients with diffuse large B-cell lymphoma treated with
immunochemotherapy.
HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant
immunochemotherapy with PSK.
Immunotherapy,
immunochemotherapy and chemotherapy for American Cutaneous Leishmaniasis treatment.
To date, the only treatment bearing curative potential is allogeneic stem cell transplantation; in contrast to conventional
immunochemotherapy, it can provide long-term disease control, even in patients with del Up or other unfavorable biological and clinical risk factors.
Supportive treatments, IVIG and sometimes
immunochemotherapy are the treatment options in IAHS (1,2).
A turkey tails polysaccharide as an
immunochemotherapy agent in cancer.
The recommended management strategy includes chemotherapy, radiotherapy, surgery and
immunochemotherapy with monoclonal antibodies.
Induction
immunochemotherapy was followed by obinutuzumab maintenance therapy.
1992, Randomized, controlled study on adjuvant
immunochemotherapy with PSK in curatively resected colorectal cancer.
DLBCL is the second most common histology of all lymphomas, and although considered aggressive in nature, it can be treated with curative intent with standard
immunochemotherapy [1].
Effect on rossette forming T-lymphocyte level in
immunochemotherapy using Picibanil and Wobe-Mugos in gastric cancer patients.
